💸 The Tape

Ten years after Massachusetts voters approved adult-use cannabis, a Virginia-based prohibition group is asking them to take it back. Question 8 on the November 3 ballot would repeal the laws authorizing licensed retail sales and home cultivation, and impose civil penalties for possession of one to two ounces. Possession of smaller amounts would stay legal and the medical program would survive, but the 400-plus dispensaries, the cultivators supplying them, and the roughly 20,000 jobs attached would be gone.

It's the first serious attempt anywhere in the country to reverse a voter-approved legalization law. For the industry, the question isn't whether the repeal is popular — it isn't — but whether a low-turnout midterm and a nine-question ballot can produce a result the polls don't predict.

Where the polls sit

Every public survey has the repeal losing, and the margin has widened as the campaign has intensified. February polling put opposition at 63%. A UMass Amherst/WCVB survey in August was the tightest at 55-33, which prompted some nervousness in the industry about an ad-driven squeeze. Then the opposite happened. A MassINC Polling Group survey for CommonWealth Beacon, fielded September 14 to 22, found 61% no and 27% yes. Three days later the University of New Hampshire's Bay State Poll landed at 71% against.

The crosstabs matter more than the toplines. Marijuana Moment's review of the Democratic-voter data showed supermajority support for keeping legalization across every age, racial, gender and geographic group polled. In a state where Democrats dominate turnout, a measure that loses every demographic cohort doesn't have a path unless opponents stay home. That's the only scenario the yes side is playing for.

The two campaigns

The Coalition for a Healthy Massachusetts is the repeal campaign, and its funding structure is the first thing anyone should know about it: it has been bankrolled almost entirely by SAM Action, the political arm of Smart Approaches to Marijuana, which committed nearly $3.2 million through August. It's the same organization running a parallel repeal petition in Maine, and the same one suing the DEA in the D.C. Circuit over the April Schedule III rule. Its argument is that legalization increased youth access and that the state's public health has suffered. Spokesperson Wendy Wakeman has spent much of the year defending the signature drive after voters reported being handed fake cover sheets for unrelated measures like affordable housing; one gatherer was caught on video and later fired.

The question survived everything the industry threw at it. The Massachusetts Cannabis Business Association accused the campaign of deceptive signature tactics and filed challenges; the Ballot Law Commission overruled an objection in January and again in July; the Legislature held a hearing in March, grilled the campaign and declined to act; the Supreme Judicial Court upheld the petition in June. By late July it had a number and a ballot slot.

Stop the Repeal is the industry response, launched June 25 on the State House steps by former Boston city councilor and dispensary owner Tito Jackson, with Ryan Dominguez as campaign chair and funding routed through the Committee to Protect Cannabis Regulation. It had raised roughly $1.54 million through August — a 2-to-1 disadvantage on the cycle, though both sides entered the fall with similar cash on hand, about $980,000 for the repeal campaign and $947,000 for the opposition. The coalition pairs dispensary owners with physicians, law enforcement and labor; the SEIU State Council endorsed the no campaign in September, which brings turnout infrastructure the industry doesn't have on its own.

The evidence on the ground

The repeal's central claim is about teenagers, and it is the claim with the least support. CDC Youth Risk Behavior Survey data released this fall shows past-month marijuana use among Massachusetts high school students has fallen by more than 50% since legalization, a steeper decline than the 44% national drop over the same period. Monitoring the Future finds eighth and tenth graders nationally report cannabis is harder to get than before adult-use markets opened — the "easy to obtain" measure is down more than 30% since 2012. The Marijuana Policy Project's state-by-state review found youth use declining in every legalization state, Massachusetts included.

The Boston Globe's reporting on the campaign's youth argument found what it describes as broad declines statewide, alongside one genuinely contrary data point: southern Berkshire County, one of the most dispensary-friendly corners of the state, reported a 70% increase in past-month use among 12th graders between 2021 and 2025. That's a local anomaly worth studying, not a statewide trend, and the researchers the Globe spoke with said as much.

On the broader harm-reduction front, the state's numbers are moving in the direction prohibition promised and never delivered. Massachusetts recorded 978 opioid-related overdose deaths in 2025, the first year under 1,000 since 2013, down 27% from 2024 and nearly 60% from the 2022 peak of 2,364. The Department of Public Health credits expanded prevention, harm reduction and treatment — the public-health infrastructure a repeal would defund by eliminating the cannabis tax revenue that helps pay for it.

What operators are actually doing

The industry's approach has three layers. The first was legal: block the question before it reached voters, which failed but delayed the repeal campaign's messaging into the summer. The second is coalition-building: the no campaign has been deliberately constructed so that the public faces are physicians, police officers, union leaders and small business owners rather than the multistate operators, and the message is about jobs, municipal tax revenue and safety — not about the right to get high.

The third is the one that will decide the race: turnout. The campaign's own framing concedes the risk — low midterm participation and a long ballot are how a minority position wins — and the response has been grassroots voter education, organizing through the dispensary customer base, and the SEIU endorsement to reach voters who aren't thinking about cannabis at all. Jackson's warning at the launch was that many businesses had dismissed the proposal as a joke. The polls say it is one. The industry is spending as though it isn't.

The read

Question 8 is on track to fail by 30 or 40 points. The relevant question for the sector is what SAM gets for its $3.2 million: a template, a fundraising story and a Maine sequel, regardless of the result. Massachusetts operators who treat November as a formality will have helped build it.

📈 Dog Walkers

$AYR Closes Ohio

Ayr Wellness (CSE: AYR.A) (OTCQX: AYRWF) closed the first transfer of its Ohio operations to Arboretum Bidco LLC on Wednesday, the latest step in a restructuring that has been dismantling the company piece by piece since last November. Arboretum is the vehicle Ayr's senior secured noteholders created to take the keys; it will keep operating under the Ayr Wellness name, and Ohio regulators signed off on the transfer before closing.

Ohio follows Virginia, Florida, New Jersey and Nevada, all of which moved to Arboretum earlier this year under the November 14, 2025 Master Purchase Agreement. What remains with the public parent is a shrinking list of assets and a stated intention to wind down the corporate entity once the transfers are complete. The press release says as much in its forward-looking language: "the wind-down of the existing AYR corporate parent entity."

The mechanics are what a lender-led restructuring looks like when there's no bankruptcy court to run it. Noteholders took the operating assets through a consensual asset purchase, state by state, with each transfer gated by regulatory approval. Equity holders are left with a shell.

Ohio is a real market, with sales running north of $100 million a month and an eight-store cap that makes existing permits valuable. For the noteholders, it's another operating asset recovered at par-plus. For Ayr shareholders, it's one more confirmation of a conclusion the market reached a year ago.

The company that once called itself a top-five MSO is now a transfer agent for its own creditors. A few more closings and there won't be anything left to transfer.

📺 Trade To Black

There's Still Major Momentum in Cannabis | TTB Presented by Flowhub

• High Tide's record quarter, from the CEO: Raj Grover breaks down $198.8 million in revenue (up 33%), record adjusted EBITDA of $16.2 million, a ~$800 million run rate, Canna Cabana's 14% market share, and Remexian's 10.2 tonnes in Germany — plus how rescheduling could open a U.S. pathway for Nasdaq-listed companies.

• Schedule III, in practice: Vantage Hemp CMO Dr. Paul Shields on certifying versus prescribing, the six-month DEA registration window, who screens for drug interactions at the counter, and why rescheduling doesn't mean insurance coverage — with Florida's medical program as the live case study.

• What the stay actually was: FundCanna CEO Adam Stettner clarifies that Judge Julius paused his recommendation, not the hearing, and shares what operators, banks, lawyers and accountants are saying since the news broke.

• Delay tactic, not a derailment: Stettner's general counsel reads the GAO motion as opponents buying time, not changing the outcome.